Literature DB >> 29297204

Role of intravoxel incoherent motion MRI in early assessment of the response of esophageal squamous cell carcinoma to chemoradiotherapy: A pilot study.

Huanhuan Zheng1, Wei Ren2, Xia Pan1, Qinglei Zhang1, Baorui Liu2, Song Liu1, Jian He1, Zhengyang Zhou1.   

Abstract

BACKGROUND: Since definitive concurrent chemoradiotherapy (CRT) is standard therapy for inoperable esophageal squamous cell carcinoma (ESCC), early evaluation of treatment response is crucial for patients and would be useful in assessing response, especially in patients with severe side effects.
PURPOSE: To explore the feasibility of intravoxel incoherent motion (IVIM) MRI in the early assessment of treatment response to CRT. STUDY TYPE: Prospective. POPULATION: Twenty-three inoperable ESCC patients. SEQUENCE: IVIM 3T MRI of nine b values (0, 25, 50, 75, 100, 150, 200, 500 and 800 s/mm2 ) was performed at four timepoints: pre-CRT (within 5 days before CRT), mid-CRT (2-3 weeks after the start of CRT), end-CRT (within 5 days after the end of CRT), and post-CRT (1 month after the end of CRT). ASSESSMENT: IVIM-based parameters and ADC were analyzed independently by two radiologists and treatment response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). STATISTICAL TESTS: Analyses of variance for repeated measurements were conducted to observe dynamic changes of IVIM-based parameters (D, f, and D*) and ADC during CRT. The parameters and their change percentages (Δ%) were compared between complete response (CR) and partial response (PR) by Mann-Whitney U-test. Diagnostic performance of parameters in predicting response was tested with receiver-operating characteristic curve analysis.
RESULTS: ADC, D, and f increased significantly during CRT (P < 0.001, < 0.001, and 0.001, respectively). ADC, f, Δ%ADC, and Δ%D at mid-CRT in CR group were significantly higher than those in the PR group (P = 0.002, 0.013, 0.005, and 0.011, respectively). D combined with f and ADC had highest area under curve (0.917) in identifying CR from PR. DATA
CONCLUSION: IVIM parameters proved useful in assessing response to definitive concurrent CRT for inoperable ESCC and combined with ADC at an early stage of treatment was a good predictor of response. LEVEL OF EVIDENCE: 2 Technical Efficacy: Stage 4 J. MAGN. RESON. IMAGING 2018;48:349-358.
© 2018 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  chemoradiotherapy; esophageal neoplasms; intravoxel incoherent motion MRI; magnetic resonance imaging; tumor response

Mesh:

Year:  2018        PMID: 29297204     DOI: 10.1002/jmri.25934

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  12 in total

1.  The value of intravoxel incoherent motion diffusion-weighted imaging in predicting the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma.

Authors:  Tao Song; Qi Yao; Jinrong Qu; Hongkai Zhang; Yan Zhao; Jianjun Qin; Wen Feng; Shouning Zhang; Xianhua Han; Shaoyu Wang; Xu Yan; Hailiang Li
Journal:  Eur Radiol       Date:  2020-09-08       Impact factor: 5.315

2.  Clinical response assessment on DW-MRI compared with FDG-PET/CT after neoadjuvant chemoradiotherapy in patients with oesophageal cancer.

Authors:  Sophie E Vollenbrock; Francine E M Voncken; Doenja M J Lambregts; Monique Maas; Maarten L Donswijk; Erik Vegt; Leon C Ter Beek; Jolanda M van Dieren; Johanna W van Sandick; Berthe M P Aleman; Regina G H Beets-Tan; Annemarieke Bartels-Rutten
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-06-22       Impact factor: 9.236

3.  Muscle-invasive bladder cancer: pretreatment prediction of response to neoadjuvant chemotherapy with diffusion-weighted MR imaging.

Authors:  Xinxin Zhang; Yichen Wang; Jin Zhang; Xiaojuan Xu; Lianyu Zhang; Miaomiao Zhang; Lizhi Xie; Jianzhong Shou; Yan Chen
Journal:  Abdom Radiol (NY)       Date:  2022-03-20

4.  ADC correlation with Sirtuin1 to assess early chemoradiotherapy response of locally advanced esophageal carcinoma patients.

Authors:  Ying Chen; Tieming Xie; Zhimin Ye; Fangzheng Wang; Dan Long; Mingxiang Jiang; Jun Fang; Qingren Lin; Kai Li; Zhun Wang; Zhenfu Fu
Journal:  Radiat Oncol       Date:  2019-11-04       Impact factor: 3.481

5.  Value of long non-coding RNA Rpph1 in esophageal cancer and its effect on cancer cell sensitivity to radiotherapy.

Authors:  Zhen-Yang Li; Hui-Fen Li; Ying-Ying Zhang; Xue-Lan Zhang; Bing Wang; Jiang-Ting Liu
Journal:  World J Gastroenterol       Date:  2020-04-21       Impact factor: 5.742

6.  Predicting Early Response to Chemoradiotherapy for Uterine Cervical Cancer Using Intravoxel Incoherent Motion MR Imaging.

Authors:  Hiroki Kato; Kae Esaki; Takahiro Yamaguchi; Hidekazu Tanaka; Kimihiro Kajita; Tatsuro Furui; Ken-Ichirou Morishige; Satoshi Goshima; Masayuki Matsuo
Journal:  Magn Reson Med Sci       Date:  2019-02-19       Impact factor: 2.471

Review 7.  Quantitative Magnetic Resonance Imaging for Biological Image-Guided Adaptive Radiotherapy.

Authors:  Petra J van Houdt; Yingli Yang; Uulke A van der Heide
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

8.  Intravoxel Incoherent Motion Model in Differentiating the Pathological Grades of Esophageal Carcinoma: Comparison of Mono-Exponential and Bi-Exponential Fit Model.

Authors:  Nian Liu; Xiongxiong Yang; Lixing Lei; Ke Pan; Qianqian Liu; Xiaohua Huang
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 6.244

9.  Predicting the effects of radiotherapy based on diffusion kurtosis imaging in a xenograft mouse model of esophageal carcinoma.

Authors:  An-Du Zhang; Xiao-Hua Su; Yan-Fei Wang; Gao-Feng Shi; Chun Han; Nan Zhang
Journal:  Exp Ther Med       Date:  2021-02-05       Impact factor: 2.447

10.  DCE-MRI radiomics nomogram can predict response to neoadjuvant chemotherapy in esophageal cancer.

Authors:  Jinrong Qu; Ling Ma; Yanan Lu; Zhaoqi Wang; Jia Guo; Hongkai Zhang; Xu Yan; Hui Liu; Ihab R Kamel; Jianjun Qin; Hailiang Li
Journal:  Discov Oncol       Date:  2022-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.